



PATENT  
ATTORNEY DOCKET NO. 50150/055003

Certificate of Mailing: Date of Deposit: January 11, 2005

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Santa Zingariello

Printed name of person mailing correspondence

*Santa Zingariello*

Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Barry Eisenstein	Art Unit:	1615
Serial No.:	10/652,799	Examiner:	Robert M. Joynes
Filed:	August 29, 2003	Customer No.:	21559
Title:	METHODS AND REAGENTS FOR TREATING INFECTIONS OF <i>CLOSTRIDIUM DIFFICILE</i> AND DISEASES ASSOCIATED THEREWITH		

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicant submits the references listed on the enclosed Form PTO-1449, copies of which are enclosed, with the exception of U.S. patents and U.S. patent application publications. A copy of a search report from a corresponding international application is also enclosed.


Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed after a first Office action on the merits, but before the mailing of a final Office action or a Notice of Allowance. A check for \$180.00 in payment of the late submission fee set forth in 37 C.F.R. § 1.17(p) is enclosed.


If there are any other charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 11 January 2005

  
Karen L. Elbing, Ph.D.  
Reg. No. 35,238

Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045



Sheet 1 of 3

SUBSTITUTE FORM PTO-1449  
(MODIFIED)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

Attorney Docket No. 50150/055003

Serial No. 10/652,799

Applicant Barry Eisenstein et al.

Filing Date August 29, 2003

Group 1651

IDS Filed January 11, 2005

Customer No. 21559

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT  
(Use several sheets if necessary)

(37 C.F.R. § 1.98(b))

U.S. PATENTS

Examiner's Initials	Patent Number or Patent Application No.	Issue Date or Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	6,506,407	1/14/03	Wantanabe et al.			
	6,488,962	12/3/02	Berner et al.			
	6,340,475	1/22/02	Shell et al.			
	6,319,518	11/20/01	Lee et al.			
	6,316,433	11/13/01	Rose et al.			
	6,270,755	8/07/01	Kurtz et al.			
	5,972,389	10/26/99	Shell et al.			
	5,968,554	10/19/99	Beiman et al.			
	5,962,024	10/5/99	Marvola et al.			
	5,849,327	12/15/98	Berliner et al.			
	5,811,388	9/22/98	Friend et al.			
	5,773,000	06/30/98	Bostwick et al.			
	5,582,837	12/10/96	Shell			
	5,547,683	8/20/96	Yano et al.			
	5,525,634	6/11/96	Sintov et al.			
	5,266,315	11/30/93	Taguchi et al.			
	5,007,790	4/16/91	Shell			
	4,983,602	01/08/91	Yamane et al.			
	2004/0034021	02/19/04	Michaelis et al.			

EXAMINER


DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to application.



Sheet 2 of 3

SUBSTITUTE PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No.	50150/055003	
		INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/652,799	
		(37 C.F.R. § 1.98(b))		Applicant	Barry Eisenstein et al.	
				Filing Date	August 29, 2003	
				Group	1651	
				IDS Filed	January 11, 2005	
				Customer No.	21559	
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
	Alfa et al., "Survey of Incidence of <i>Clostridium difficile</i> Infection in Canadian Hospitals and Diagnostic Approaches," <i>J. Clin. Microbiol.</i> 36:2076-2080 (1998).					
	Anton et al., "Rifaxen Prevents and Treats <i>Clostridium difficile</i> -Associated Infection in Hamsters," Abstract ID No. 102471, Publishing ID No. T1741, presented at the American Gastroenterological Association Meeting.					
	Anton et al., "Rifaxen Prevents and Treats <i>Clostridium difficile</i> -Associated Infection in Hamsters," Abstract, presented at the Digestive Disease Weekly Annual Meeting, May 2003.					
	Bartlett et al., "Clindamycin-Associated Colitis Due to a Toxin-Producing Species of <i>Clostridium</i> in Hamsters," <i>J. Infect. Dis.</i> 136:701-705 (1977).					
	Bartlett et al., "Treatment of Antibiotic-Associated Pseudomembranous Colitis," <i>Rev. Infect. Dis.</i> 6:S235-S241 (1984).					
	Boon et al., "Studies with Temocillin in the Hamster Model of Antibiotic-Associated Colitis," <i>Drugs</i> 29 (Suppl. 5) 57-63 (1985).					
	Buggy et al., "Therapy of Relapsing <i>Clostridium difficile</i> -Associated Diarrhea and Colitis with the Combination of Vancomycin and Rifampin," <i>J. Clin. Gastroenterol.</i> 9:155-159 (1987).					
	Declaration of Barry Eisenstein					
	Fekety, R. "Guidelines for the Diagnosis and Management of <i>Clostridium difficile</i> -Associated Diarrhea and Colitis," Practice Parameters Committee," <i>Am. J. Gastroenterol.</i> 92:739-750 (1997).					
	Fujii et al., "In Vitro and In Vivo Antibacterial Activities of KRM-1648 and KRM-1657, New Rifamycin Derivatives," <i>Antimicrob. Agents Chemother.</i> 38:1118-1122 (1994).					
	Gorbach et al., "Successful Treatment of Relapsing <i>Clostridium difficile</i> Colitis with <i>Lactobacillus GG</i> ," <i>Lancet</i> 2:1519 (1987).					
	Hirata et al., "In Vitro and In Vivo Activities of the Benzoxazinorifamycin KRM-1648 against <i>Mycobacterium tuberculosis</i> ," <i>Antimicrob. Agents Chemother.</i> 39:2295-2303 (1995).					
	Kelly et al., " <i>Clostridium difficile</i> Colitis," <i>N. Engl. J. Med.</i> 330:257-262 (1994).					
	Klemens et al., "Activity of KRM-1648 in Combination with Isoniazid Against <i>Mycobacterium tuberculosis</i> in a Murine Model," <i>Antimicrob. Agents Chemother.</i> 40:298-301 (1996).					
	Kunimoto et al., "Recurrent <i>Clostridium difficile</i> -Associated Colitis Responding to Cholestyramine," <i>Digestion</i> 33:225-228 (1986).					
	Kurtz et al., "GT160-246, a Toxin Binding Polymer for Treatment of <i>Clostridium difficile</i> Colitis," <i>Antimicrob. Agents Chemother.</i> 45:2340-2347 (2001).					
	Kyne et al., " <i>Clostridium difficile</i> ," <i>Gastroenterol. Clinics</i> 30:1-25 (2001).					
	Kyne et al., "Recurrent <i>Clostridium difficile</i> Diarrhoea," <i>Gut</i> 49:152-153 (2001).					
EXAMINER			DATE CONSIDERED			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						



Sheet 3 of 3

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No.	50150/055003
		INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/652,799
		(37 C.F.R. § 1.98(b))		Applicant	Barry Eisenstein et al.
				Filing Date	August 29, 2003
				Group	1651
				IDS Filed	January 11, 2005
				Customer No.	21559
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)					
	Lai et al., <i>Clostridium difficile</i> -Associated Diarrhea: Epidemiology, Risk Factors, and Infection Control," <i>Infect. Control Hosp. Epidemiol.</i> 18:628-632 (1997).				
	Lenaerts et al., "Evaluation of Rifalazil in a Combination Treatment Regimen as an Alternative to Isoniazid-Rifampin Therapy in a Mouse Tuberculosis Model," <i>Antimicrob. Agents Chemother.</i> 44:3167-3168 (2000).				
	Leung et al., "Treatment with Intravenously Administered Gamma Globulin of Chronic Relapsing Colitis Induced by <i>Clostridium difficile</i> Toxin," <i>J. Pediatr.</i> 118:633-637 (1991).				
	McFarland et al., "Breaking the Cycle: Treatment Strategies for 163 Cases of Recurrent <i>Clostridium difficile</i> Disease," <i>Am. J. Gastroenterol.</i> 97:1769-1775 (2002).				
	McFarland et al., "A Randomized Placebo-Controlled Trial of <i>Saccharomyces boulardii</i> in Combination with Standard Antibiotics for <i>Clostridium difficile</i> Disease," <i>JAMA</i> 271:1913-1918 (1994).				
	McVay et al., "In Vitro and In Vivo Activities of Nitazoxanide Against <i>Clostridium difficile</i> ," <i>Antimicrob. Agents Chemother.</i> 44:2254-2258 (2000).				
	National Committee for Clinical Laboratory Standards, Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria, Approved Standard M11-A5, 5 <sup>th</sup> ed. (2001).				
	Olson et al., Ten years of Prospective <i>Clostridium difficile</i> Associated Disease Surveillance and Treatment at the Minneapolis VA Medical Center 1982-1991," <i>Infect. Control Hosp. Epidemiol.</i> 15:371-381 (1994).				
	Peterson et al., "Antimicrobial Agents in <i>Clostridium difficile</i> -Associated Intestinal Disease," <i>Antimicrob. Agents</i> 115-127 (1991).				
	Pothoulakis, C., "Pathogenesis of <i>Clostridium difficile</i> Associated Diarrhoea," <i>Eur. J. Gastroenterol. Hepatol.</i> 8:1041-1047, (1996).				
	Pothoulakis et al., "CP-96, 345, a Substance P Antagonist, Inhibits Rat Intestinal Responses to <i>Clostridium difficile</i> Toxin A But Not Cholera Toxin," <i>Proc. Natl. Acad. Sci.</i> 91:947-951 (1994).				
	Pothoulakis et al., "Microbes and Microbial Toxins: Paradigms for Microbial-Mucosal Interactions II. The Integrated Response of the Intestine to <i>Clostridium difficile</i> Toxins," <i>Am. J. Physiol. Gastronointest. Liver Physiol.</i> 280:178-183 (2001).				
	"Recommendations for Preventing the Spread of Vancomycin Resistance: Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC)," <i>Am. J. Infect. Control</i> 23:87-94 (1995).				
	Sambol et al., "Infection of Hamsters with Epidemiologically Important Strains of <i>Clostridium difficile</i> ," <i>J. Infect. Dis.</i> 183:1760-1766 (2001).				
	Samore, "Epidemiology of Nosocomial <i>Clostridium difficile</i> Diarrhoea," <i>J. Hosp. Infect.</i> 43:S183-S190 (1999).				
	Teasley et al., "Prospective Randomised Trial of Metronidazole Versus Vancomycin for <i>Clostridium difficile</i> -associated Diarrhoea and Colitis," <i>Lancet</i> 2:1043-1046 (1983).				
	Tedesco et al., "Approach to Patients with Multiple Relapses of Antibiotic-Associated Pseudomembranous Colitis," <i>Am. J. Gastroenterol.</i> 80:867-868 (1985).				
	Wilcox et al., "Recurrence of Symptoms in <i>Clostridium difficile</i> Infection--Relapse or Reinfection?" <i>J. Hosp. Infect.</i> 38:93-100 (1998).				
	Zimmerman et al., "Review Article: Treatment of <i>Clostridium difficile</i> Infection," <i>Aliment. Pharmacol. Ther.</i> 11:1003-1012 (1997).				
EXAMINER		DATE CONSIDERED			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.					